Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kbl Merger Corp IV WT (KBLMW)

Kbl Merger Corp IV WT (KBLMW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -90 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KBLMW with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 07/02/19
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1612 +6.70%
on 11/03/20
0.2650 -35.09%
on 10/23/20
-0.0680 (-28.33%)
since 10/06/20
3-Month
0.1518 +13.31%
on 08/07/20
0.3300 -47.88%
on 09/21/20
+0.0220 (+14.67%)
since 08/06/20
52-Week
0.0358 +380.45%
on 05/21/20
0.6400 -73.13%
on 06/30/20
+0.0920 (+115.00%)
since 11/06/19

Most Recent Stories

More News
SPAC Merger Fires Boosters for 180 Life Sciences’ Exploration in Unmet Medical Needs of Anti-inflammatories Space

Clinical stage biotechnology company  180 Life Sciences Corp. , whose scientific teams are led by drug developers renowned for producing some of the largest-selling pharmaceuticals to ever come to market,...

KBLM : 4.99 (-17.52%)
KBLMR : 0.3920 (+3.19%)
KBLMW : 0.1720 (-3.37%)
Innovative Companies with Blockbuster Potential Catch SPAC Attention

NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio – 180 Life Sciences Corp., a clinical-stage biotechnology company that has entered into a definitive merger agreement with KBL Merger Corp....

KBLMW : 0.1720 (-3.37%)
KBLMR : 0.3920 (+3.19%)
KBLM : 4.99 (-17.52%)
In Pursuit of the Elusive Drug — the Billion-Dollar Blockbuster

NetworkNewsWire Editorial Coverage : Enormous amounts of money exchange hands in the big pharma space as companies merge and are acquired — all in search of the next blockbuster drug. While the discovery...

KBLMR : 0.3920 (+3.19%)
KBLMW : 0.1720 (-3.37%)
KBLM : 4.99 (-17.52%)
ALXN : 182.50 (+1.70%)
GILD : 64.58 (-0.52%)
LLY : 771.55 (-0.45%)
VRTX : 418.99 (+0.04%)
UPDATE -- The Quest for Blockbuster Drugs Continues

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire — 180 Life Sciences Corp., a clinical-stage biotechnology company that has entered into a definitive merger agreement with KBL Merger...

KBLMW : 0.1720 (-3.37%)
KBLMR : 0.3920 (+3.19%)
KBLM : 4.99 (-17.52%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar